ALBUQUERQUE, NM--(Marketwire - February 28, 2012) -
IntelliCyt Corporation, a leading life science technology provider of innovative high-throughput cell-based screening solutions, has launched a unique suite of screening kits to address the rapidly growing biologics market. The new MultiCyt Screening Kits, used with the HTFC® Screening System which combines high sensitivity with single cell measurements, address challenges and limitations associated with legacy platforms.
The MultiCyt Hybridoma Screening Kit is a powerful, mix-and-measure solution for primary screening of hybridoma libraries, designed to test antibody binding directly on living cells. This high-throughput solution allows scientists to detect antibodies that bind to unique conformational epitopes that may be missed with current ELISA assays.
The MultiCyt Count and Capture - IgG Secretion Screening Kit is a novel multiplexed screening assay that provides a single platform solution for researchers assessing productivity of antibody-secreting cell lines. By simultaneously measuring the amount of secreted protein and providing a viable cell count, the amount of antibody produced can be determined on a per-cell basis in one assay, saving valuable time and resources in the cell line generation process.
The MultiCyt Cell Encoder Screening Kit enables multiple cell lines to be color coded and combined into screening plates to test target-specific clone binding characteristics and select those with the greatest promise for pre-clinical and clinical trials. Using the HTFC Screening System, the cell lines are combined and tested within the same wells, enabling scientists to simultaneously analyze the biology of each encoded cell line.
"The new screening assays take advantage of our proprietary technologies to quickly make concurrent measurements on individual cells at rates of thousands of cells per second, providing anywhere from 1-6 readouts per sample," said Thomas Duensing, Ph.D., Vice President of Product Development.
The IntelliCyt approach to screening assays addresses the need to obtain more answers with smaller amounts of sample. By using far less sample than current methods, coupled with more information, the IntelliCyt assay kits, in conjunction with the HTFC platform, achieve significant productivity increases and provide better decision-making capabilities. "Our technology provides a valuable solution to the therapeutic antibody community by answering multiple questions on a single platform, addressing bottlenecks resulting from repetitive screening testing on multiple platforms, as well as reducing costs and improving time to results. Our technology will redefine what users can accomplish from their screening campaigns," said R. Terry Dunlay, CEO of IntelliCyt.
About IntelliCyt Corporation
IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, assays, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells and beads. IntelliCyt's products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences. The company's corporate headquarters are located at 9620 San Mateo Blvd NE, Albuquerque, NM 87113. For more information, please visit www.intellicyt.com.